Investor Relations

International Red Dot jury recognizes the design excellence of Ambu’s newly launched video laryngoscope solution, SureSight™, emphasizing its coherent system architecture.

Copenhagen, Denmark, 30 April 2026 – Ambu, the global market leader in single-use endoscopy, today announces that its SureSight video laryngoscope solution has received the prestigious Red Dot Design Award: Product Design 2026, one of the world’s most respected distinctions for high design quality.

The Red Dot Jury selected SureSight from a global field of submissions, recognizing the solution for its coherent system architecture, which combines ergonomic instrument handling and reliable high-quality imaging with a modular system.

The award reinforces Ambu’s strong focus on translating real customer needs into customer‑centric design as a foundation for developing differentiated solutions. Through deliberate design choices, Ambu continues to improve even well‑established clinical concepts and strengthen its leading offering within Respiratory.

SureSight is designed as a unified solution for difficult intubations, developed to support clinicians in time‑critical airway situations where reliability, ease of use, and clear visualization are essential. The solution consists of two video laryngoscopes, SureSight Connect and SureSight Mobile, and ten single-use SureSight blades, together forming a coherent solution with integrated imaging as well as procedural photos and video transfer capabilities to ease documentation.

Designed as a part of Ambu’s Respiratory platform, it can be used on its own as a video laryngoscope or together with Ambu bronchoscopes in a dual‑view setup on Ambu’s endoscopy systems. By bringing video laryngoscopy and bronchoscopy together on a single technology platform, clinicians can work with familiar interfaces and obtain efficient workflows whether in the operating room, ICU, or emergency settings. This integrated approach reduces setup complexity and helps clinical teams stay focused on the patient.

“This Red Dot Design Award is a testament to Ambu’s ability to design solutions that stand out to our customers,” says Britt Meelby Jensen, Chief Executive Officer of Ambu. “SureSight reflects our strong customer‑centric approach and a focus on developing differentiated solutions grounded in real clinical needs. I’m very proud of our global teams across Ambu who made this achievement possible.”

This recognition marks Ambu’s third Red Dot Design Award for solutions in its leading single-use endoscopy portfolio. In 2021, Ambu received the Product Design award for both its single‑use cystoscope, aScope™ 4 Cysto, and its single‑use duodenoscope, aScope™ Duodeno, acknowledging the solutions’ high design quality and functionality in single‑use endoscopy.

Ambu launched SureSight in the USA and the UK in 2025 and is now gradually rolling out across Europe after receiving CE mark earlier this month.

Read and download the full press release here.

The SureSight™ portfolio strengthens Ambu’s Respiratory platform in Europe by offering clinicians and hospitals a fully integrated video laryngoscopy portfolio for difficult airway intubations.

Copenhagen, Denmark, 20 April 2026 – Ambu, the global mark, today announces receipt of a CE Mark and the upcoming gradual roll out of its entire SureSight video laryngoscope portfolio in Europe.

First launched in the USA and the UK in 2025, and now in the rest of Europe, the SureSight portfolio is designed to provide a clear airway view and support intubation in multiple healthcare settings, including the operating room (OR), intensive care unit (ICU), and emergency medical services (EMS). Video laryngoscopy combines advanced visualization of the glottis with ease of use, helping clinicians see the airway more clearly and achieve higher first-pass intubation success rates.¹

While video laryngoscopy accounts for roughly 50% of all procedures in the U.S., it accounts for approximately one in 10 procedures in Europe, where it is primarily used for difficult airway intubations. However, its adoption as a standard intubation tool is increasing.

“The development of video laryngoscopy represented a significant advancement within airway management and has since become a gold standard practice. With the new SureSight portfolio, Ambu has integrated the option of video laryngoscopy into their existing respiratory platform, which is now capable of facilitating simultaneous usage with the aScope Broncho or VivaSight 2 devices to support a combined intubation technique across a single screen. The addition of the SureSight Mobile also ensures universal access to a video laryngoscope across a wide range of clinical settings for unexpected and unplanned procedures,” says Dr George Christodoulides, Consultant Anaesthetist, Guy’s and St Thomas’ NHS Foundation Trust, London, UK².

The Ambu SureSight portfolio includes two complementary solutions: SureSight Connect and SureSight Mobile, both compatible with 10 single-use SureSight blades. SureSight Connect offers dual-view intubation with video laryngoscopy and the use of a single-use bronchoscope on one screen – ideal for teamwork and training, while streamlining complex procedures and reducing equipment requirements. Complimentarily, SureSight Mobile is a compact, portable video laryngoscope with a built-in screen, designed for rapid, ready-to-use deployment across hospital wards and emergency settings.

In addition, SureSight also helps clinicians document intubation directly and transfer images and videos to electronic health records in hospitals. This integrated documentation capability is designed to further enhance workflow efficiency, allowing clinicians to maximize their focus on the patient. 

Britt Meelby Jensen, CEO of Ambu, states, “Now that the entire SureSight portfolio is available across Europe, we're enhancing our Respiratory platform with an integrated video laryngoscopy solution. This offering supports clinicians in working both efficiently and confidently during challenging airway intubations. I am thrilled to introduce these comprehensive solutions within Europe, further solidifying our leadership in single-use endoscopy.
 

¹ Ruetzler K, Bustamante S, Schmidt MT, et al. Video Laryngoscopy vs Direct Laryngoscopy for Endotracheal Intubation in the Operating Room: A Cluster Randomized Clinical Trial. JAMA. 2024;331(15):1279–1286. doi:10.1001/jama.2024.0762

² Dr. Christodoulides has not been compensated for his quote in this press release.

Read and download the full press release here.

On 10 December 2025, Ambu announced a share buyback program (company announcement no. 7 2025/26). The share buyback program was carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.

During the program, Ambu has repurchased shares for a total amount of DKK 150m since 10 December 2025. The program had to be completed no later than 31 March 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.

The following transactions have been made under the program from 9 February to 11 February 2026:
 

After the above mentioned transactions, the share buyback program has now been concluded. Ambu now owns 4,195,158 treasury shares, corresponding to 1.6% of the share capital.

Download the company announcement here.